Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

FHS
June 19, 2023
2:43 pm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).

Gene editing delivery biotech GenEdit partners with Genentech, raises another $24M

Gene editing still needs better delivery systems, more than half a dozen years after Kunwoo Lee recalls CRISPR pioneer Jennifer Doudna telling attendees at a

January 24, 2024

Pharmalittle: Pharma likely to expand legal attacks on Medicare negotiations; CDC recommends rationing RSV drug

Good morning, everyone, and how are you today? We are doing just fine, thank you. After all, the birds are still chirping and a cool

October 25, 2023

Eating vegetables and fruits significantly reduces sarcopenia risk, meta-analysis shows

The association between vegetable and fruit consumption and the risk of sarcopenia.

June 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.